Nathan N. O'HAra

Nathan N. O'HAra

Auto-generated profile, based on publicly available information

Nathan N. O'HAra

Department of Orthopaedics, University of California – Irvine, Irvine, California

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NONathan N O'Hara
Nathan N O'Hara
MIMarckenley Isaac
Marckenley Isaac
GSGerard P Slobogean
Gerard P Slobogean
NKNiek S Klazinga
Niek S Klazinga
The overall objective of this study was to determine the patient-level socioeconomic impact resulting from orthopaedic trauma in the available literature. The MEDLINE, Embase, and Scopus databases were searched in December 2019. Studies were eligible for inclusion if more than 75% of the study population sustained an appendicular fracture due to an acute trauma, the mean age was 18 through 65 years, and the study included a socioeconomic outcome, defined as a measure of income, employment status, or educational status. Two independent reviewers performed data extraction and quality assessment. Pooled estimates of the socioeconomic outcome measures were calculated using random-effects models with inverse variance weighting. Two-hundred-five studies met the eligibility criteria. These studies utilized five different socioeconomic outcomes, including return to work (n = 119), absenteeism days from work (n = 104), productivity loss (n = 11), income loss (n = 11), and new unemployment (n = 10). Pooled estimates for return to work remained relatively consistent across the 6-, 12-, and 24-month timepoint estimates of 58.7%, 67.7%, and 60.9%, respectively. The pooled estimate for mean days absent from work was 102.3 days (95% CI: 94.8–109.8). Thirteen-percent had lost employment at one-year post-injury (95% CI: 4.8–30.7). Tremendous heterogeneity (I2>89%) was observed for all pooled socioeconomic outcomes. These results suggest that orthopaedic injury can have a substantial impact on the patient’s socioeconomic well-being, which may negatively affect a person’s psychological wellbeing and happiness. However, socioeconomic recovery following injury can be very nuanced, and using only a single socioeconomic outcome yields inherent bias. Informative and accurate socioeconomic outcome assessment requires a multifaceted approach and further standardization.

3 August 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BHBryce E. Haac
Bryce E. Haac
NONathan N. O'HAra
Nathan N. O'HAra
TMTheodore T. Manson
Theodore T. Manson
GSGerard P. Slobogean
Gerard P. Slobogean
RCRenan C. Castillo
Renan C. Castillo
OIon behalf of the ADAPT Investigators
on behalf of the ADAPT Investigators
Emerging evidence suggests aspirin may be an effective venous thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer bleeding complications. We used a patient-centered weighted composite outcome to globally evaluate aspirin versus low-molecular-weight heparin (LMWH) for VTE prevention in fracture patients. We conducted an open-label randomized clinical trial of adult patients admitted to an academic trauma center with an operative extremity fracture, or a pelvis or acetabular fracture. Patients were randomized to receive LMWH (enoxaparin 30-mg) twice daily (n = 164) or aspirin 81-mg twice daily (n = 165). The primary outcome was a composite endpoint of bleeding complications, deep surgical site infection, deep vein thrombosis, pulmonary embolism, and death within 90 days of injury. A Global Rank test and weighted time to event analysis were used to determine the probability of treatment superiority for LMWH, given a 9% patient preference margin for oral administration over skin injections. Overall, 18 different combinations of outcomes were experienced by patients in the study. Ninety-nine patients in the aspirin group (59.9%) and 98 patients in the LMWH group (59.4%) were event-free within 90 days of injury. Using a Global Rank test, the LMWH had a 50.4% (95% CI, 47.7–53.2%, p = 0.73) probability of treatment superiority over aspirin. In the time to event analysis, LMWH had a 60.5% probability of treatment superiority over aspirin with considerable uncertainty (95% CI, 24.3–88.0%, p = 0.59). The findings of the Global Rank test suggest no evidence of superiority between LMWH or aspirin for VTE prevention in fracture patients. LMWH demonstrated a 60.5% VTE prevention benefit in the weighted time to event analysis. However, this difference did not reach statistical significance and was similar to the elicited patient preferences for aspirin.

1 May 2020 in Injury
Verified
Journal Article
Closed access
NONathan N O'HAra
Nathan N O'HAra
JRJohn T. Richards
John T. Richards
AOArchie Overmann
Archie Overmann
GSGerard P. Slobogean
Gerard P. Slobogean
NKNiek S. Klazinga
Niek S. Klazinga

1 October 2021 in The American Journal of Medicine
Verified
Journal Article
Closed access
JSJennifer Y. So
Jennifer Y. So
NONathan N. O'HAra
Nathan N. O'HAra
BKBlaine Kenaa
Blaine Kenaa
JWJohn G. Williams
John G. Williams
CDChristopher L. Deborja
Christopher L. Deborja
Robert M. ReedRobert M. Reed
Robert M. Reed

1 December 2019 in Injury
Verified
Journal Article
Closed access
AOA.L. Overmann
A.L. Overmann
JRJ.T. Richards
J.T. Richards
NON.N. O'HAra
N.N. O'HAra
JDJ.C. D'ALleyrand
J.C. D'ALleyrand
GSG.P. Slobogean
G.P. Slobogean

1 April 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
NONathan N. O’hAra
Nathan N. O’hAra
End-of-life care often includes a constellation of supportive care options marred by conflicting concerns among patients, their families, and health care profes